Australian Gonococcal Surveillance Programme, 1 July to 30 September 2018

Monica M Lahra; Rodney P Enriquez; C R Robert George, The World Health Organisation Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, New South Wales Health Pathology, Microbiology and The Prince of Wales Hospital, Randwick, NSW, 2031 for The National Neisseria Network, Australia

# Introduction

The National Neisseria Network (NNN), Australia comprises reference laboratories in each State and Territory that report data on susceptibilities for an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The antibiotics are penicillin, ceftriaxone, azithromycin and ciprofloxacin and represent current or potential agents used for the treatment of gonorrhoea. Azithromycin combined with ceftriaxone is the recommended treatment regimen for gonorrhoea in the majority of Australia. However, there are substantial geographic differences in susceptibility patterns in Australia with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxicillin, probenecid and azithromycin is recommended for the treatment of gonorrhoea. Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP has a programme-specific quality assurance process.

# Results

A summary of the proportion of isolates with decreased susceptibility to ceftriaxone (MIC 0.06-0.25 mg/L), and the proportion resistant to azithromycin (MIC ≥1.0 mg/L), penicillin (MIC ≥1.0 mg/L), and ciprofloxacin (MIC ≥1.0 mg/L) for Quarter 3 2018 are shown in Table 1.

Table 1: Gonococcal isolates showing decreased susceptibility to ceftriaxone, and resistance to azithromycin, penicillin, and ciprofloxacin, Australia, 1 July to 30 September 2018, by State or Territory.

| State or Territory | Number of isolates tested | Decreased Susceptibility | | Resistance | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Q3, 2018 | Ceftriaxone  MIC  0.06-0.25 mg/L | | Azithromycin  MIC  ≥1.0 mg/L | | Penicillin\* MIC  ≥1.0 mg/L | | Ciprofloxacin MIC  ≥1.0 mg/L | |
| n | % | n | % | n | % | n | % |
| Australian Capital Territory | 44 | 2 | 4.5 | 1 | 2.3 | 6 | 13.6 | 5 | 11.4 |
| New South Wales | 950 | 9 | 0.9 | 78 | 8.2 | 218 | 22.9 | 291 | 30.6 |
| Queensland | 352 | 2 | 0.6 | 16 | 4.5 | 67 | 19.0 | 91 | 25.9 |
| South Australia | 48 | 1 | 2.1 | 2 | 4.2 | 9 | 18.8 | 16 | 33.3 |
| Tasmania | 14 | 1 | 7.1 | 1 | 7.1 | 1 | 7.1 | 4 | 28.6 |
| Victoria | 644 | 23 | 3.6 | 61 | 9.5 | 125 | 19.4 | 159 | 24.7 |
| Northern Territory Urban & Rural | 13 | 0 | 0 | 0 | 0 | 1 | 7.7 | 2 | 15.4 |
| Northern Territory Remote | 51 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2.0 |
| Western Australia Urban & Rural | 141 | 3 | 2.1 | 3 | 2.1 | 25 | 17.7 | 31 | 22.0 |
| Western Australia Remote | 32 | 0 | 0 | 0 | 0 | 1 | 3.1 | 0 | 0 |
| AUSTRALIA | 2,289 | 41 | 1.8 | 162 | 7.1 | 453 | 19.8 | 600 | 26.2 |

\* Penicillin resistance includes MIC value of ≥1.0 mg/L, or penicillinase production.

## Ceftriaxone

For the AGSP the category of ceftriaxone decreased susceptibility (DS) includes the MIC values 0.06-0.25 mg/L. The breakpoint for ceftriaxone resistance is yet to be determined. In the third quarter of 2018, the proportion of isolates with ceftriaxone DS in Australia was 1.55%, slightly higher than the proportion in the first and second quarters of 2018, and slightly higher than the annual proportion for 2017 (Table 2). There were no isolates reported in the second or third quarters of 2018 in Australia with an MIC >0.125 mg/L. Of note, there were two isolates exhibited DS to ceftriaxone (MIC = 0.06mg/L) and resistance to azithromycin, one from Victoria, and one from urban/rural Western Australia. One of these isolates, from urban Western Australia, was also resistant to penicillin, but sensitive to ciprofloxacin.

Table 2: Percentage of gonococcal isolates with decreased susceptibility to ceftriaxone (MIC 0.06 and ≥0.125 mg/L), Australia, 2011 to 2017, 1 January to 31 March 2018, 1 April to 30 June 2018, and 1 July to 30 September 2018.

| Ceftriaxone MIC mg/L | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 Q1 | 2018 Q2 | 2018 Q3 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 0.06 | 4.10% | 8.20% | 4.80% | 1.70% | 1.65% | 1.02% | 1.60% | 1.55% | 1.70% |
| ≥0.125 | 0.30% | 0.60% | 0.60% | 0.10% | 0.05% | 0.04% | 0.10% | 0% | 0.09% |

The national trend of isolates with ceftriaxone decreased susceptibility (MIC 0.06 and ≥0.125 mg/L) since 2012 is shown in Table 2.

A summary of ceftriaxone DS strains that were penicillin and ciprofloxacin resistant, or isolated from extragenital sites (rectal and pharyngeal) for Quarter 3, 2018 by state or territory, and by sex (male/female) is shown in Table 3.

Table 3: Percentage of gonococcal isolates with decreased susceptibility to ceftriaxone (MIC ≥0.06 mg/L) and that were penicillin (Pen) and ciprofloxacin (Cip) resistant (R), isolated from extragenital sites, and by sex, Australia, Australia, 1 July to 30 September 2018.

| Strains with ceftriaxone decreased susceptibility (CRO DS) | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| State or Territory | Total | Pen R + Cip R | | Males | | Females | | Extragenital sites | |
| n | % | n | % | n | % | n | % |
| Australian Capital Territory | 2 | 0 | 0 | 2 | 100 | 0 | 0 | 2 | 100 |
| New South Wales | 9 | 6 | 67 | 8 | 89 | 1 | 11 | 0 | 0 |
| Queensland | 2 | 2 | 100 | 2 | 100 | 0 | 0 | 0 | 0 |
| South Australia | 1 | 0 | 0 | 1 | 100 | 0 | 0 | 1 | 100 |
| Tasmania | 1 | 1 | 100 | 1 | 100 | 0 | 0 | 1 | 100 |
| Victoria | 23 | 19 | 83 | 16 | 70 | 7 | 30 | 8 | 35 |
| Northern Territory Urban & Rural | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Northern Territory Remote | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Western Australia Urban & Rural | 3 | 2 | 67 | 1 | 33 | 2 | 67 | 1 | 33 |
| Western Australia Remote | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AUSTRALIA | 41 | 30 | 73.2 | 31 | 75.6 | 10 | 24.4 | 13 | 31.7 |

## Azithromycin

In the third quarter of 2018, the proportion of isolates with resistance to azithromycin (MIC ≥1.0 mg/L) in Australia was 7.1%, higher than the proportion reported nationally in the first and second quarters of 2018, but lower than for 2017 (9.3%), and three times the level reported in Australia for 2013-2015 (2.1%-2.6%) (Table 4).1 Globally there have been increasing reports of azithromycin resistance in N. gonorrhoeae.2

Table 4: Percentage of gonococcal isolates with resistance to azithromycin (MIC ≥1.0 mg/L), Australia, 2012 to 2017, 1 January to 31 March 2018, 1 April to 30 June 2018, and 1 July to 30 September 2018.

| Azithromycin Resistance | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 Q1 | 2018 Q2 | 2018 Q3 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MIC ≥1 mg/L | 1.3% | 2.1% | 2.5% | 2.6% | 5.0% | 9.3% | 6.0% | 5.8% | 7.1% |

In quarter 3 2018, most states reported isolates with resistance to azithromycin, with the exception of Northern Territory and remote Western Australia. The states that reported an increase in the number and proportion of N. gonorrhoeae isolates with resistance to azithromycin when compared with the previous quarter of 2018 were New South Wales, Australian Capital Territory, Tasmania, and South Australia. There were two isolates that exhibited resistance to azithromycin and DS to ceftriaxone (MIC = 0.064 mg/L). One of these isolates, from urban Western Australia, was also resistant to penicillin, but sensitive to ciprofloxacin. There were no isolates in this quarter that exhibited high level resistance to azithromycin (MIC ≥256 mg/L).

The national trend of azithromycin resistance in isolates since 2012 is shown in Table 4.

Dual therapy using ceftriaxone plus azithromycin is the recommended treatment for gonorrhoea as a strategy to temper development of more widespread resistance. Patients with infections in extragenital sites, where the isolate has decreased susceptibility to ceftriaxone, should have test of cure cultures collected. Continued surveillance to monitor N. gonorrhoeae with elevated MIC values, coupled with sentinel site surveillance in high risk populations remains important to inform therapeutic strategies, to identify incursion of resistant strains, and to detect instances of treatment failure.

# References

1. Lahra MM, Enriquez RP. Australian Gonococcal Surveillance Programme. Annual Report 2016. Commun Dis Intell (2018). 2018;42(4):PII:S2209-6051(18)00013-1.
2. Unemo M. Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15:364.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Cindy Toms

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

**Website**: <http://www.health.gov.au/cdi>

**Contacts**Communicable Diseases Intelligence is produced by:   
Health Protection Policy Branch, Office of Health Protection, Australian Government Department of Health  
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2019 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: [copyright@health.gov.au](mailto:copyright@health.gov.au)

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.  
<http://www.health.gov.au/cdna>